Nixon Peabody
Bank of America
You are here:  Home  >  Biotech  >  Current Article

Amgen discontinues Alzheimer’s prevention drug trials

By   /   Thursday, July 11th, 2019  /   Comments Off on Amgen discontinues Alzheimer’s prevention drug trials

    Print       Email
Thousand Oaks biotech giant Amgen, along with partners Novartis and Banner Alzheimer’s Institute, are discontinuing a clinical research program that was aimed at preventing or delaying the onset of Alzheimer’s disease in at-risk individuals. The company announced the news in a July 11 news release, which stated that “after a review of clinical data, sponsors…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Atara to raise $175M in secondary public offering

Read More →